No registrations found.
ID
Source
Health condition
ABO-incompatible kidney transplantation.
Dutch:
bloedgroep ABO-incompatible niertransplantatie.
Sponsors and support
Erasmus Medical Center Rotterdam
Erasmus Medical Center Rotterdam
Intervention
Outcome measures
Primary outcome
- To compare the number of biopsy-proven acute rejections (BPAR) within three months after ABOi kidney transplantation in rituximab versus alemtuzumab treated patients.
Secondary outcome
- To compare infectious complications after ABOi kidney transplantation in rituximab versus alemtuzumab treated patients.
- T compare renal function one year after ABOi kidney transplantation in rituximab versus alemtuzumab treated patients.
Study objective
Alemtuzumab induction therapy in ABOi kidney transplantation lowers the incidence of cellular-mediated BPAR compared to rituximab induction, without affecting the number of antibody-mediated rejections.
Study design
t=0
t=3 months
t=12 months
Intervention
observational study
Erasmus Medical Center <br>
Room D-411 <br>
Postbus 2040 <br>
A.E. Weerd, de
Rotterdam 3000 CA
The Netherlands
0031-10-7034607
a.deweerd@erasmusmc.nl
Erasmus Medical Center <br>
Room D-411 <br>
Postbus 2040 <br>
A.E. Weerd, de
Rotterdam 3000 CA
The Netherlands
0031-10-7034607
a.deweerd@erasmusmc.nl
Inclusion criteria
Recipients of an ABO-incompatible kidney transplant aged 18 years or older.
Exclusion criteria
Recipients of an ABO-compatible kidney allograft.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL5268 |
| NTR-old | NTR5384 |
| Other | : MEC-2015-246 |